Nigerian Ministry of Health delegation accompanies Afreximbank on a visit to the AMCE project site to assess progress.

Categories: Press Releases

Nigeria, 6 June 2023 – The Honorable Minister of Health, Nigeria, Dr. Osagie Ehanire – accompanied by AMCE Executives, including CEO Brian Deaver, and representatives of Afreximbank – inspected the construction site of the African Medical Centre of Excellence (AMCE) in Abuja to assess the progress made in setting up this pioneering institution, ahead of its final commissioning in the second quarter of 2025.

Dr. Osagie, while noting that the Federal Government of Nigeria was proud to be supporting the project implementation, visited the construction site with the sole purpose of examining and evaluating the progress achieved thus far, in order to provide an  assessment to Nigeria’s President H.E. Muhammadu Buhari. At the end of his visit, the Honorable Minister expressed his pleasure at the quality of work at the site, remarking on the positive impact that the project would have on the healthcare sector in the country.

The AMCE project, a collaboration with King’s College Hospital, London (KCH), aims to provide world-class care to patients across the African continent by performing innovative and ground-breaking research, development and educational programs in partnership with leading global institutions. Once complete, the centre will offer a full spectrum of services in oncology, haematology, cardiovascular, and general healthcare across the continent, with Abuja serving as the headquarters for other AMCEs to be launched across Africa.

The primary objective of the AMCE project is to reduce medical tourism and capital outflows by offering advanced medical procedures such as stem cell transplantation for sickle cell patients, state-of-the-art diagnostic and treatment options for various cancers, and advanced technologies like high brachytherapy, linear accelerators, and positron emission tomography.

Brian Deaver, CEO of the African Medical Centre of Excellence (AMCE), said:

“I express my sincere gratitude to Honorable Minister of Health, Dr. Ehanire for taking the time to visit the AMCE site in person and for all the support the project has received from the Federal Government of Nigeria and the Ministry of Health. The success of the AMCE will pave the way for future investments and partnerships in the health and research sector while raising the local standard of healthcare and providing a blueprint for the quality of services required to address Nigeria and Africa’s healthcare and broader economic challenges.”


About Afreximbank

African Export-Import Bank (Afreximbank) is a Pan-African multilateral financial institution mandated to finance and promote intra-and extra-African trade. For 30 years, the Bank has been deploying innovative structures to deliver financing solutions that support the transformation of the structure of Africa’s trade, accelerating industrialization and intra-regional trade, thereby boosting economic expansion in Africa. A stalwart supporter of the African Continental Free Trade Agreement (AfCFTA), Afreximbank has launched a Pan-African Payment and Settlement System (PAPSS) that was adopted by the African Union (AU) as the payment and settlement platform to underpin the implementation of the AfCFTA. Working with the AfCFTA Secretariat and the AU, the Bank is setting up a US$10 billion Adjustment Fund to support countries to effectively participate in the AfCFTA. At the end of 2022, Afreximbank’s total assets and guarantees stood at over US$31 billion, and its shareholder funds amounted to US$5.2 billion. The Bank disbursed more than US$86 billion between 2016 and 2022. Afreximbank has investment grade ratings assigned by GCR (international scale) (A), Moody’s (Baa1), Japan Credit Rating Agency (JCR) (A-) and Fitch (BBB). Afreximbank has evolved into a group entity comprising the Bank, its impact fund subsidiary called the Fund for Export Development Africa (FEDA), and its insurance management subsidiary, AfrexInsure, (together, “the Group”).

For more information, visit:

Follow us on Twitter | Facebook | LinkedIn | Instagram